T. Jeroen N. Hiltermann

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge et al. · Nature Medicine · 2018 · 734 citations · Full text

Medicine, Oncology, Pharmacology +17

Characteristics of the Inhibition of NADPH Oxidase Activation in Neutrophils by Apocynin, a Methoxy-Substituted Catechol

Jan Stolk, T. Jeroen N. Hiltermann, Joop H. Dijkman et al. · American Journal of Respiratory Cell and Molecular Biology · 1994 · 643 citations

Life Sciences, Cell Biology, Immunology +16

The detection of EpCAM+ and EpCAM– circulating tumor cells

Sanne de Wit, Guus van Dalum, Aufried Lenferink et al. · Scientific Reports · 2015 · 296 citations · Full text

Medicine, Cell Biology, Oncology +17

Immune microenvironment composition in non‐small cell lung cancer and its association with survival

Menno Tamminga, T. Jeroen N. Hiltermann, Ed Schuuring et al. · Clinical & Translational Immunology · 2020 · 227 citations · Full text

Medicine, Immunology, Oncology +17

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido et al. · Journal of Thoracic Oncology · 2022 · 226 citations · Full text

Medicine, Oncology, Pharmacotherapy +16